Hany Ahmed
Houston, TXNPI 1528038916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $420 and has fallen 76.3% since, to $100 in 2025.
Across 62 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$214
- Astellas Pharma US Inc$136
- Bayer$121
- Medtronic$109
- Shield Therapeutics Inc$96
- Baxter Healthcare$93
- plus $667 from 19 others
Across 301 payments — averaging $8177.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.6M
- Pfizer$867K
What the payments were for
- Food & beverage$1,34193%
- Education$947%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $214 |
| Astellas Pharma US Inc | 4 | $136 |
| Bayer | 5 | $121 |
| Medtronic | 1 | $109 |
| Shield Therapeutics Inc | 5 | $96 |
| Baxter Healthcare | 2 | $93 |
| Hologic Sales And Service, LLC | 5 | $87 |
| Merck | 5 | $80 |
| Myovant Sciences Inc. | 4 | $80 |
| Caldera Medical, Inc | 1 | $68 |
| Mission Pharmacal Company | 3 | $45 |
| Pacira Pharmaceuticals Incorporated | 2 | $41 |
| Organon | 2 | $32 |
| Smith+Nephew | 1 | $25 |
| Coopersurgical, Inc. | 2 | $25 |
| Abbott | 1 | $23 |
| Pfizer | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Scynexis, Inc. | 1 | $19 |
| Alafair Biosciences, Inc. | 1 | $19 |
| Acessa Health Inc. | 1 | $18 |
| Millicent US Inc | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Meditrina | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-LOC 180$109
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibandronate Sodium | 23 | $1,539 |
| Estradiol | 30 | $1,484 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $394 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $150 |
| Fluconazole | 29 | $106 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.